Association of the HLA-DQA1*05 Allelic Gene Variants with Immunogenicity to Anti-TNF therapeutics-Important Differences Between Infliximab and Adalimumab.
作者信息
Ternette Nicola, Liao Hanqing, Satsangi Jack
机构信息
School of Life Sciences, University of Dundee, Dundee, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
出版信息
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjae172.
Abstract
摘要
相似文献
1
Association of the HLA-DQA1*05 Allelic Gene Variants with Immunogenicity to Anti-TNF therapeutics-Important Differences Between Infliximab and Adalimumab.HLA-DQA1*05等位基因变体与抗TNF治疗药物免疫原性的关联——英夫利昔单抗和阿达木单抗之间的重要差异
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjae172.
2
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.HLA-DQA1*05 携带与克罗恩病患者对英夫利昔单抗和阿达木单抗的药物抗体发展相关。
Gastroenterology. 2020 Jan;158(1):189-199. doi: 10.1053/j.gastro.2019.09.041. Epub 2019 Oct 7.
3
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.携带HLA-DQA1⋆05单倍型与炎症性肠病患者接受抗TNF治疗时药物浓度低于治疗水平及更高的免疫原性风险相关。
Therap Adv Gastroenterol. 2024 Oct 16;17:17562848241278145. doi: 10.1177/17562848241278145. eCollection 2024.
4
HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies.来自SERENE溃疡性结肠炎和克罗恩病研究的炎症性肠病患者中，HLA-DQA1*05与抗肿瘤坏死因子免疫原性及阿达木单抗低谷浓度相关。
J Crohns Colitis. 2025 Jan 11;19(1). doi: 10.1093/ecco-jcc/jjae129.
5
Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs.HLADQA1*05在接受抗TNF药物治疗的炎症性肠病患者中的作用。
Medicina (Kaunas). 2025 Jan 13;61(1):102. doi: 10.3390/medicina61010102.
6
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.抗 TNF 治疗克罗恩病患者应答丧失的机制和管理：前瞻性、多中心 PANTS 队列研究的 3 年数据。
Lancet Gastroenterol Hepatol. 2024 Jun;9(6):521-538. doi: 10.1016/S2468-1253(24)00044-X. Epub 2024 Apr 16.
7
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.HLADQA1*05 基因型对接受 TNF 拮抗剂主动药物监测的炎症性肠病成年患者的影响：一项回顾性队列研究。
Inflamm Bowel Dis. 2023 Oct 3;29(10):1586-1593. doi: 10.1093/ibd/izac259.
8
HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn's disease.HLA-DQA1*05与中国克罗恩病患者抗药物抗体产生风险增加及英夫利昔单抗反应降低相关。
Gastroenterol Rep (Oxf). 2024 Jul 24;12:goae074. doi: 10.1093/gastro/goae074. eCollection 2024.
9
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.生物治疗药物的测序和炎症性肠病患者选择二线抗 TNF 治疗的意义：来自于第二代抗 TNF 治疗免疫原性（IMSAT）治疗药物监测研究的结果。
Aliment Pharmacol Ther. 2022 Oct;56(8):1250-1263. doi: 10.1111/apt.17170. Epub 2022 Aug 29.
10
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.HLA-DQA1*05 与炎症性肠病患者对首用抗 TNF 治疗的原发性无应答或应答丢失无关。
Inflamm Bowel Dis. 2024 Jun 3;30(6):922-929. doi: 10.1093/ibd/izad130.
引用本文的文献
1
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients.对HLA基因型在炎症性肠病患者免疫原性及抗TNF治疗继发性难治性中作用的分子洞察
Int J Mol Sci. 2025 Jul 28;26(15):7274. doi: 10.3390/ijms26157274.
本文引用的文献
1
HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies.来自SERENE溃疡性结肠炎和克罗恩病研究的炎症性肠病患者中，HLA-DQA1*05与抗肿瘤坏死因子免疫原性及阿达木单抗低谷浓度相关。
J Crohns Colitis. 2025 Jan 11;19(1). doi: 10.1093/ecco-jcc/jjae129.
2
Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab".效力不足的 PANTS：对“扩展分析确定两种不同 HLA II 类单倍型与阿达木单抗和英夫利昔单抗免疫原性发展的药物特异性关联”结论的回应
Gastroenterology. 2021 Jan;160(1):470-471. doi: 10.1053/j.gastro.2020.05.102. Epub 2020 Oct 3.
3
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab.扩展分析确定了与阿达木单抗和英夫利昔单抗免疫原性发展相关的2种不同HLA II类单倍型的药物特异性关联。
Gastroenterology. 2020 Aug;159(2):784-787. doi: 10.1053/j.gastro.2020.03.073. Epub 2020 Apr 8.
Zotero 插件